Literature DB >> 10868970

Early glomerular macrophage recruitment in streptozotocin-induced diabetic rats.

C Sassy-Prigent1, D Heudes, C Mandet, M F Bélair, O Michel, B Perdereau, J Bariéty, P Bruneval.   

Abstract

Diabetic glomerulosclerosis is defined by increased glomerular extracellular matrix (ECM) that is mainly synthesized by mesangial cells that underwent an activation mediated by cytokines and growth factors from various cellular origins. In this study, we tested whether macrophages could infiltrate the glomeruli and influence ECM synthesis in experimental diabetes. To test our hypothesis, we initially studied the dynamics of glomerular macrophage recruitment in streptozotocin-induced diabetic rats at days 1, 2, 4, 8, 15, and 30 by using quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) on isolated glomeruli and immunohistochemistry and morphometry. We then assessed the role of macrophages on the basis of the pharmacological modulation of their recruitment by insulin or ACE inhibitor treatments and by X-irradiation-induced macrophage depletion at days 8 and 30. Macrophages were recruited within the glomeruli at the very early phase of hyperglycemia by using RT-PCR CD14 detection from day 2 and by using ED1 immunohistochemistry from day 8. This glomerular macrophage infiltration was associated with an increase in alpha1-chain type IV collagen mRNA. In parallel, the diabetic glomeruli became hypertrophic with an increase in the mesangial area. Macrophage recruitment was preceded by or associated with an increased glomerular expression of vascular cell adhesion molecule 1, intracellular adhesion molecule 1, and monocyte chemoattractant protein 1, which contributes to monocyte diapedesis. Glomerular interleukin-1beta mRNA synthesis was also enhanced as early as day 1 and could be involved in the increase in ECM and adhesion molecule gene expressions. Insulin treatment and irradiation-induced macrophage depletion completely prevented the glomerular macrophage recruitment and decreased alpha1-chain type IV collagen mRNA and mesangial area in diabetic rats, whereas ACE inhibitor treatment had an incomplete effect. It can be concluded that in the streptozotocin model, hyperglycemia is followed by an early macrophage recruitment that contributes to the molecular and structural events that could lead to glomerulosclerosis. Therefore, besides direct stimulation of mesangial cells by hyperglycemia, macrophages recruited in the glomeruli during the early phase of hyperglycemia could secondarily act on mesangial cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10868970     DOI: 10.2337/diabetes.49.3.466

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  98 in total

1.  Renoprotective effects of clarithromycin via reduction of urinary MCP-1 levels in type 2 diabetic patients.

Authors:  Atsuhito Tone; Kenichi Shikata; Koichi Nakagawa; Masaaki Hashimoto; Hirofumi Makino
Journal:  Clin Exp Nephrol       Date:  2010-11-03       Impact factor: 2.801

2.  Deletion of soluble epoxide hydrolase gene improves renal endothelial function and reduces renal inflammation and injury in streptozotocin-induced type 1 diabetes.

Authors:  Ahmed A Elmarakby; Jessica Faulkner; Mohammed Al-Shabrawey; Mong-Heng Wang; Krishna Rao Maddipati; John D Imig
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-08-10       Impact factor: 3.619

3.  Anti-inflammatory and Antioxidative Activities of Safranal in the Reduction of Renal Dysfunction and Damage that Occur in Diabetic Nephropathy.

Authors:  Ömer Hazman; Mehmet Fatih Bozkurt
Journal:  Inflammation       Date:  2015-08       Impact factor: 4.092

4.  Gingival levels of monocyte chemoattractant protein-1 (MCP-1) in diabetes mellitus and periodontitis: an experimental study in rats.

Authors:  Elif Eser Sakallioğlu; Bülent Ayas; Müge Lütfioğlu; Gonca Cayir Keleş; Gökhan Açikgöz; Erhan Firatli
Journal:  Clin Oral Investig       Date:  2007-09-18       Impact factor: 3.573

5.  Renal proximal tubular epithelial cell transforming growth factor-beta1 generation and monocyte binding.

Authors:  Xiao Liang Zhang; Wisam Selbi; Carol de la Motte; Vincent Hascall; Aled Phillips
Journal:  Am J Pathol       Date:  2004-09       Impact factor: 4.307

6.  Gene expression programs of mouse endothelial cells in kidney development and disease.

Authors:  Eric W Brunskill; S Steven Potter
Journal:  PLoS One       Date:  2010-08-10       Impact factor: 3.240

7.  Diabetic nephropathy is accelerated by farnesoid X receptor deficiency and inhibited by farnesoid X receptor activation in a type 1 diabetes model.

Authors:  Xiaoxin X Wang; Tao Jiang; Yan Shen; Yupanqui Caldas; Shinobu Miyazaki-Anzai; Hannah Santamaria; Cydney Urbanek; Nathaniel Solis; Pnina Scherzer; Linda Lewis; Frank J Gonzalez; Luciano Adorini; Mark Pruzanski; Jeffrey B Kopp; Jill W Verlander; Moshe Levi
Journal:  Diabetes       Date:  2010-08-10       Impact factor: 9.461

8.  Vasohibin-1, a negative feedback regulator of angiogenesis, ameliorates renal alterations in a mouse model of diabetic nephropathy.

Authors:  Tatsuyo Nasu; Yohei Maeshima; Masaru Kinomura; Kumiko Hirokoshi-Kawahara; Katsuyuki Tanabe; Hitoshi Sugiyama; Hikaru Sonoda; Yasufumi Sato; Hirofumi Makino
Journal:  Diabetes       Date:  2009-07-08       Impact factor: 9.461

9.  MCP-1 and RANTES polymorphisms in Korean diabetic end-stage renal disease.

Authors:  Kwon Wook Joo; Young Hwan Hwang; Jae Hyeon Kim; Kook Hwan Oh; Hyunho Kim; Hyoung Doo Shin; Woo Kyung Chung; Jaeseok Yang; Kyong Soo Park; Curie Ahn
Journal:  J Korean Med Sci       Date:  2007-08       Impact factor: 2.153

10.  Effect of the monocyte chemoattractant protein-1/CC chemokine receptor 2 system on nephrin expression in streptozotocin-treated mice and human cultured podocytes.

Authors:  Elena Tarabra; Sara Giunti; Federica Barutta; Gennaro Salvidio; Davina Burt; Giacomo Deferrari; Roberto Gambino; Daniela Vergola; Silvia Pinach; Paolo Cavallo Perin; Giovanni Camussi; Gabriella Gruden
Journal:  Diabetes       Date:  2009-07-08       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.